STOMACH AND DUODENUM: Edited by Tilak U. ShahGastric submucosal mass lesionsDesai, Nikitaa; Monsrud, Ashleyb; Willingham, Field F.c Author Information aEmory Department of Medicine bEmory Department of Pathology and Laboratory Medicine cEmory Department of Medicine, Division of Digestive Diseases, Emory University, Atlanta, Georgia, USA Correspondence to Field F. Willingham, MD, MPH, FASGE, Associate Division Director for Academic Affairs, Director of Endoscopy, Emory University Hospital, Medical Director of Therapeutic Endoscopy, Children's Healthcare of Atlanta, Professor of Medicine, Emory University School of Medicine, Department of Medicine, Division of Digestive Diseases, 1365 Clifton Road, NE, Building B Suite 1200, Atlanta, GA 30322, USA. Tel: +1 404 778 3184; fax: +1 404 778 2925; e-mail: [email protected] Current Opinion in Gastroenterology: November 2022 - Volume 38 - Issue 6 - p 581-587 doi: 10.1097/MOG.0000000000000877 Buy Metrics Abstract Purpose of review Gastric submucosal mass lesions are a collection of tumours that arise in the stomach and are deep to the mucosal layer. Distinct from gastric epithelial carcinomas, these tumours are generally more indolent. They are often found incidentally on upper endoscopy. Most often they present as smooth protuberant masses covered by normal intact gastric mucosa. The majority are asymptomatic. Endoscopic ultrasound (EUS) is frequently employed to further characterize the lesions. EUS can be diagnostic of some lesions, such as lipomas, and can be used to guide fine needle aspiration to diagnose others. Adding to the traditional management approaches of observation and surgical resection, numerous new and emerging endoscopic therapies are now being used to resect these gastric tumours. Recent findings This review focuses on evolving strategies in the diagnosis and management of submucosal mass lesions. Although surgical intervention was once the lone option for intervention, there are an increasing number of endoscopic therapies. There have also been advancements in neoadjuvant therapies and in distinguishing the malignant potential of submucosal mass lesions. Summary Gastric submucosal lesions are common. EUS is frequently indicated in the evaluation and diagnosis. For tumours for which observation is not recommended, novel endoscopic therapies may offer less invasive management options. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.